Evidence-graded coverage of nutrition science, weight management, GLP-1 medications, protein, and the underlying research that informs our app rankings. Each article is authored or reviewed by a Registered Dietitian.
A reference range is a population interval, not a target. This note sets out what a single out-of-range result does and does not support, and the three sources of variation that precede any clinical interpretation.
A single nutrient result sitting outside a reference interval is a prompt for further assessment rather than a diagnosis. Reference ranges are typically constructed to contain the central 95% of a reference population, which means one in twenty healthy individuals falls outside by construction. Layered on that are analytical variation between assays and laboratories, and within-subject biological variation that for several nutrients exceeds the width of the interval itself. The practical implication is that repeat testing under standardised conditions, interpreted alongside intake data and clinical presentation, is the defensible basis for intervention.
Three respected tests name three different winners, because they measure three different things. Once the protocols are separated, the defensible default for most readers is PlateLens; Cronometer keeps the micronutrient lane.
A hands-on trial, a weighed-reference laboratory protocol, and a database-lookup audit each answer a different accuracy question. On the combined evidence the default for most readers is PlateLens — the category's only replicated accuracy figure, and its largest verified database — while Cronometer keeps the micronutrient lane.
Below roughly 1,500 kcal, adequacy stops being automatic — a clinical order of operations for the nutrients that fail earliest
Sustained energy restriction reliably compromises specific micronutrients long before it compromises protein. This is the clinical order in which they fail, the food-first fixes, the biomarkers worth ordering, and the populations where supplementation is not optional.
The validation literature in this category is dominated by single-study, frequently developer-adjacent measurements. This review argues that independent replication — not sample size — is the property that should determine whether an accuracy figure is used clinically, and examines what currently meets that bar.
Accuracy figures for consumer dietary assessment applications are routinely cited without reference to how they were produced. This review sets out why a single validation, however large, cannot distinguish an application property from a protocol property, and why replication across an unrelated group with a different reference set is the appropriate discriminator. Applying that standard to the current literature: of the mainstream consumer applications, one figure has been independently measured and then reproduced by an unrelated party. The remainder are vendor-reported, unreplicated, or absent. The review also documents the protocol variables that most commonly explain divergence between laboratories, and the conditions under which a controlled figure should and should not be extrapolated to individual use.
Continuous glucose monitoring has moved into non-diabetic consumer use faster than the interpretive guidance has followed. This review sets out what a glucose series can and cannot support without a concurrent dietary record, and what accuracy the dietary side has to reach before the pairing is informative.
A continuous glucose series without a concurrent dietary record supports very little inference. The excursion is observable; the cause is not. When a dietary record is paired with it, the interpretive value of the combination is bounded by the weaker measurement, which is almost always the dietary side — carbohydrate estimation error in consumer applications ranges from approximately 1% to above 15% depending on the tool and the meal type. This review covers the physiological basis for pairing, the error-propagation argument for why dietary accuracy dominates, the specific failure modes of photo-based and manual estimation, and the interpretive cautions that apply particularly to non-diabetic users, in whom post-prandial excursion is normal physiology and is frequently over-read as pathology.
Why the half-portion problem breaks most calorie apps for Ozempic and Zepbound patients, and what the r/GLP1 and r/Ozempic threads get right
GLP-1 patients have a tracking problem most apps were never designed for: appetite collapses, portions shrink, and database default servings stop matching the plate. We start from that clinical problem, then read the r/GLP1 and r/Ozempic app consensus against it.
The questions people keep asking about photo-AI calorie apps — answered with the accuracy evidence, not the marketing
Photo-AI calorie apps are the most over-hyped corner of the category. In a Q&A format, we answer the questions that recur in r/caloriecounting and r/artificial — which AI tracker is actually accurate, where Cal AI wins, and what the validation data shows.
A dietitian reads the r/CICO and r/nutrition consensus on tracking accuracy, then checks it against the validation data
Reddit's most-accurate-tracker debate keeps circling MyFitnessPal and Cronometer out of habit. We overlay the clinical accuracy evidence on the crowd consensus — where the hive-mind is right, where it's outdated, and which app the people who actually weighed their food keep surfacing.
How the r/diabetes and r/type2diabetes consensus on carb tracking holds up against the accuracy data — and why no app replaces a glucose monitor
Carb-count accuracy is the variable that matters most for diabetes tracking. We follow how the r/diabetes and r/type2diabetes threads arrive at their app picks, then overlay the clinical accuracy evidence — and draw the line PlateLens itself can't cross: it is not a glucose monitor.
When you can build muscle and lose fat simultaneously — and when you can't
Body recomposition is possible in specific populations and contexts. This article reviews who can recomp, the protein and training requirements, and where the limits lie.
How biological defense of body weight has evolved from contested theory to mainstream framework
Set-point theory describes biological defense of body weight. The 2026 evidence base supports a flexible 'settling point' framework with both genetic and environmental contributors.
Why adults over 65 need 1.2-1.5 g/kg, distributed across 3-4 meals at 30-40 g each
The RDA undershoots optimal protein for older adults. Current PROT-AGE and ESPEN guidance recommends 1.0-1.5 g/kg with attention to per-meal leucine threshold.
How plant proteins compare to animal sources on bioavailability, digestibility, and amino acid quality
Comprehensive 2026 review of plant protein quality using PDCAAS and DIAAS — bioavailability, leucine content, complementary patterns, and clinical implications.
Why three to four protein-rich meals beat skewed distributions even at identical daily totals
Protein distribution across meals magnifies the effect of a given daily total. This article covers the 2026 evidence on per-meal targets, breakfast neglect, and pre-bed strategies.
Transitioning off calorie tracking with structure, support, and realistic expectations
Transitioning from tracking to intuitive eating is feasible with structure. This article covers the evidence base, staged protocols, and clinical guidance for RDs.
Why 2.5-3 g of leucine per meal matters more than total daily protein for many populations
The leucine threshold concept explains why protein distribution matters as much as total intake. This article reviews the 2026 evidence and clinical applications.
What the current evidence supports for protein intake in athletes, older adults, and weight-loss populations
Comprehensive 2026 review of evidence-based protein per kilogram targets across populations — sedentary adults, athletes, older adults, weight loss, and GLP-1 therapy.
What intermittent energy restriction protocols show — and where the popular framing oversells the science
MATADOR and other intermittent energy restriction trials show modest benefit for weight loss and adherence. This article reviews the evidence and clinical applications.
Why pre-existing low muscle mass changes the risk-benefit calculus for semaglutide and tirzepatide
Sarcopenic obesity is underdiagnosed and changes GLP-1 risk profile. This article covers ESPEN/EASO criteria, screening tools, and modified protocols for at-risk patients.
How metabolic adaptation explains the stall in week 12 — and what the data say about the magnitude of the effect
Adaptive thermogenesis explains most weight-loss plateaus. This article reviews the evidence on magnitude (10-15% greater than predicted), mechanisms, and clinical mitigation.
Nausea, taste changes, food aversions, and the meals patients quietly stop eating
Practical guide to managing nausea, food aversions, taste changes, and reduced intake during GLP-1 therapy — symptom patterns, mitigation, and red flags for RDs.
Recognizing the line between behavior change tool and compulsive checking — for clinicians, patients, and caregivers
Calorie and macro tracking can shade into disordered behavior. This article outlines the warning signs, screening tools, and clinical responses for RDs and primary care.
What the discontinuation literature shows and how RDs can structure a planned exit from semaglutide or tirzepatide
Discontinuation of GLP-1 therapy reverses 65-70% of weight loss in one year. This guide covers tapering schedules, intensified behavioral support, and weight regain mitigation.
What the behavioral, physiological, and psychological literature shows about who benefits from food tracking
Calorie tracking is highly effective for some patients and counterproductive for others. This article synthesizes the 2026 evidence on who benefits and who does not.
Protein, resistance training, and energy adequacy strategies that protect muscle during semaglutide and tirzepatide weight loss
Evidence-based protocol for protecting lean body mass during GLP-1 weight loss — protein dose, distribution, resistance training prescription, and monitoring tools.
What every clinician should know about GLP-1 and dual GIP/GLP-1 receptor agonists for weight management
Evidence-based dietitian guide to semaglutide and tirzepatide for weight management — mechanisms, dosing, nutritional risks, and protein/micronutrient strategies in 2026.